Welcome to our dedicated page for Celldex Therapeutics news (Ticker: CLDX), a resource for investors and traders seeking the latest updates and insights on Celldex Therapeutics stock.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) generates frequent news as it advances antibody-based therapies in immunology, with a particular emphasis on mast cell–driven diseases. Company updates often center on barzolvolimab, a humanized monoclonal antibody targeting the KIT receptor on mast cells, and CDX-622, a bispecific antibody that neutralizes thymic stromal lymphopoietin (TSLP) and depletes mast cells via stem cell factor (SCF) starvation.
News coverage for Celldex commonly includes clinical trial milestones across multiple indications. For barzolvolimab, the company reports data from Phase 2 studies in chronic spontaneous urticaria (CSU) and chronic inducible urticarias such as cold urticaria (ColdU) and symptomatic dermographism (SD), describing statistically significant improvements in urticaria activity scores, provocation tests and quality-of-life measures, along with favorable safety profiles. Investors and clinicians can also follow announcements about the global Phase 3 EMBARQ-CSU program in CSU and the registrational Phase 3 EMBARQ-ColdU and SD program in ColdU and SD.
Additional Celldex news items highlight expansion of the barzolvolimab program into prurigo nodularis and atopic dermatitis, as well as strategic decisions such as discontinuing development in eosinophilic esophagitis (EoE) after a Phase 2 study showed mast cell depletion without clinical benefit. Updates on CDX-622 provide insight into early-stage safety, pharmacokinetics and pharmacodynamics, including sustained reductions in serum tryptase in healthy volunteers.
Corporate news may feature quarterly financial results, leadership appointments and participation in healthcare and investor conferences. For readers tracking CLDX, this news stream offers a view into Celldex’s progress in mast cell biology, the evolution of its clinical pipeline and key regulatory and financial disclosures. Bookmarking this page allows ongoing access to company-issued press releases and related market-relevant developments.
Celldex Therapeutics (NASDAQ:CLDX) reported significant progress in its pipeline during Q1 2020, despite COVID-19 challenges. The company completed enrollment in the Phase 1 study of its KIT inhibitor, CDX-0159, set for presentation at the EAACI Annual Congress 2020. Celldex plans to expand CDX-0159's development for chronic urticaria and is preparing for a Phase 1 study of CDX-527 in advanced cancers. Q1 2020 financials showed revenues of $2.7 million, primarily from a $1.8 million milestone payment, while net loss decreased to $12.6 million. Celldex's cash is sufficient to fund operations into Q2 2021.
Celldex Therapeutics (NASDAQ: CLDX) announced that results from the Phase 1 study of CDX-0159 will be presented as a late-breaking poster at the EAACI Annual Congress 2020, taking place digitally from June 6-8, 2020. The study shows that CDX-0159, an anti-KIT monoclonal antibody, achieves dose-dependent reductions in serum tryptase levels, indicating a favorable safety profile. Following promising results, Celldex plans to expand CDX-0159's development into Phase 1b studies for chronic spontaneous and inducible urticaria.